Free Trial

Amicus Therapeutics (FOLD) Financials

Amicus Therapeutics logo
$6.90 +0.18 (+2.68%)
Closing price 04:00 PM Eastern
Extended Trading
$6.80 -0.10 (-1.45%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Amicus Therapeutics

Annual Income Statements for Amicus Therapeutics

This table shows Amicus Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-132 -200 -284 -356 -277 -250 -237 -152 -56
Consolidated Net Income / (Loss)
-132 -200 -284 -356 -277 -250 -237 -152 -56
Net Income / (Loss) Continuing Operations
-132 -200 -284 -356 -277 -250 -237 -152 -56
Total Pre-Tax Income
-132 -204 -449 -356 -274 -242 -242 -150 -29
Total Operating Income
-130 -182 -442 -304 -247 -206 -212 -77 25
Total Gross Profit
0.00 4.13 31 160 230 271 291 362 475
Total Revenue
0.00 4.96 37 182 261 306 329 399 528
Operating Revenue
- 4.96 37 182 261 306 329 399 528
Total Cost of Revenue
0.00 0.83 6.24 22 31 34 39 37 53
Operating Cost of Revenue
- 0.83 6.24 22 31 34 39 37 53
Total Operating Expenses
130 186 473 464 477 478 503 439 450
Selling, General & Admin Expense
47 71 89 170 156 193 213 275 323
Research & Development Expense
77 105 149 286 308 272 277 152 109
Depreciation Expense
1.83 3.24 3.59 4.78 8.85 6.21 5.34 7.87 8.55
Other Operating Expenses / (Income)
- - 0.00 0.00 - 0.26 0.00 - 0.00
Impairment Charge
- 0.00 465 - 0.00 0.00 6.62 1.13 0.00
Restructuring Charge
0.02 0.07 - - - - 0.00 0.00 9.19
Other Special Charges / (Income)
4.38 6.76 -234 3.30 3.14 6.51 1.08 2.58 0.00
Total Other Income / (Expense), net
-1.68 -22 -7.14 -52 -27 -35 -30 -73 -54
Interest Expense
1.58 5.40 17 19 22 32 37 64 50
Interest & Investment Income
0.93 1.60 4.10 10 3.23 0.51 3.02 7.08 5.41
Other Income / (Expense), net
-1.03 -18 6.01 -43 -8.06 -2.90 4.18 -16 -9.44
Income Tax Expense
- -3.74 -165 0.48 2.60 8.91 -5.47 1.48 27
Basic Earnings per Share
($1.20) ($1.49) ($1.85) ($1.48) ($1.07) ($0.92) ($0.82) ($0.51) ($0.18)
Weighted Average Basic Shares Outstanding
109.92M 134.40M 153.36M 240.42M 258.87M 271.42M 289.06M 295.16M 304.38M
Diluted Earnings per Share
($1.20) ($1.49) ($1.85) ($1.48) ($1.07) ($0.92) ($0.82) ($0.51) ($0.18)
Weighted Average Diluted Shares Outstanding
109.92M 134.40M 153.36M 240.42M 258.87M 271.42M 289.06M 295.16M 304.38M
Weighted Average Basic & Diluted Shares Outstanding
109.92M 134.40M 153.36M 240.42M 258.87M 280.03M 282.71M 295.38M 300.12M

Quarterly Income Statements for Amicus Therapeutics

This table shows Amicus Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-33 -56 -53 -43 -22 -34 -48 -16 -6.73 15
Consolidated Net Income / (Loss)
-33 -56 -53 -43 -22 -34 -48 -16 -6.73 15
Net Income / (Loss) Continuing Operations
-33 -56 -53 -43 -22 -34 -48 -16 -6.73 15
Total Pre-Tax Income
-29 -70 -53 -41 -25 -32 -44 0.11 6.79 7.93
Total Operating Income
-34 -42 -38 -19 -17 -3.69 -28 15 22 16
Total Gross Profit
68 79 79 85 94 104 97 115 128 135
Total Revenue
82 88 86 95 104 115 110 127 142 150
Operating Revenue
82 88 86 95 104 115 110 127 142 150
Total Cost of Revenue
13 9.38 6.94 9.11 9.95 11 14 11 13 15
Operating Cost of Revenue
13 9.38 6.94 9.11 9.95 11 14 11 13 15
Total Operating Expenses
102 121 117 104 111 108 125 100 107 119
Selling, General & Admin Expense
47 54 74 65 66 70 88 74 75 87
Research & Development Expense
53 64 41 35 41 35 28 25 26 30
Depreciation Expense
1.29 1.31 1.26 2.21 2.23 2.18 2.15 2.18 2.17 2.04
Total Other Income / (Expense), net
4.58 -28 -16 -22 -7.68 -28 -16 -15 -15 -8.04
Interest Expense
9.62 11 12 12 13 27 12 13 13 12
Interest & Investment Income
0.56 1.97 2.20 1.74 1.47 1.67 1.54 1.37 1.08 1.42
Other Income / (Expense), net
14 -19 -6.19 -11 3.83 -2.63 -4.97 -3.72 -3.26 2.51
Income Tax Expense
4.02 -14 -0.29 2.72 -3.13 2.18 4.84 16 14 -6.81
Basic Earnings per Share
($0.12) ($0.19) ($0.18) ($0.15) ($0.07) ($0.11) ($0.16) ($0.05) ($0.02) $0.05
Weighted Average Basic Shares Outstanding
289.22M 289.06M 291.34M 292.80M 295.76M 295.16M 302.90M 303.77M 304.69M 304.38M
Diluted Earnings per Share
($0.12) ($0.19) ($0.18) ($0.15) ($0.07) ($0.11) ($0.16) ($0.05) ($0.02) $0.05
Weighted Average Diluted Shares Outstanding
289.22M 289.06M 291.34M 292.80M 295.76M 295.16M 302.90M 303.77M 304.69M 304.38M
Weighted Average Basic & Diluted Shares Outstanding
280.95M 282.71M 284.58M 287.12M 293.25M 295.38M 296.20M 296.59M 298.81M 300.12M

Annual Cash Flow Statements for Amicus Therapeutics

This table details how cash moves in and out of Amicus Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents
45 118 -136 30 64 20 83 -96 97 -33
Net Cash From Operating Activities
-100 -150 -214 -300 -250 -233 -202 -167 -69 -34
Net Cash From Continuing Operating Activities
-100 -150 -214 -300 -249 -233 -202 -167 -69 -34
Net Income / (Loss) Continuing Operations
-132 -200 -284 -349 -356 -277 -250 -237 -152 -56
Consolidated Net Income / (Loss)
-132 -200 -284 -349 -356 -277 -250 -237 -152 -56
Depreciation Expense
1.83 3.24 3.59 4.22 4.78 8.85 6.21 5.34 7.87 8.55
Amortization Expense
- 2.69 9.70 11 2.55 1.79 2.49 2.63 2.62 2.26
Non-Cash Adjustments To Reconcile Net Income
11 39 483 35 85 62 51 101 101 110
Changes in Operating Assets and Liabilities, net
19 4.81 -426 -1.43 15 -29 -12 -39 -29 -99
Net Cash From Investing Activities
-145 -4.51 -171 -121 95 -14 79 92 98 -0.56
Net Cash From Continuing Investing Activities
-145 -4.51 -171 -121 95 -14 79 92 98 -0.56
Purchase of Property, Plant & Equipment
-4.82 -5.95 -4.53 -6.31 -20 -3.23 -3.88 -3.77 -7.44 -3.55
Purchase of Investments
-290 -220 -490 -578 -384 -365 -341 -243 -92 -115
Sale of Property, Plant & Equipment
- - - - - 0.00 0.00 3.41 0.00 0.00
Sale and/or Maturity of Investments
290 221 324 464 499 355 424 336 197 118
Net Cash From Financing Activities
291 273 247 451 218 263 212 -7.46 62 5.12
Net Cash From Continuing Financing Activities
291 273 247 451 218 263 212 -7.46 62 5.12
Repayment of Debt
-15 -80 -0.31 0.00 0.00 -155 0.00 0.00 -408 0.00
Issuance of Debt
50 273 0.00 147 0.00 386 0.00 0.00 387 0.00
Issuance of Common Equity
243 97 243 295 189 0.00 0.00 0.00 63 20
Other Financing Activities, net
15 -15 6.30 12 32 32 212 -7.46 19 -14
Effect of Exchange Rate Changes
- - - - - - -5.05 - - -4.03
Cash Interest Paid
0.61 2.99 7.42 7.50 17 25 30 34 36 59
Cash Income Taxes Paid
- - - 1.06 0.69 10 20 1.61 8.53 8.21

Quarterly Cash Flow Statements for Amicus Therapeutics

This table details how cash moves in and out of Amicus Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
42 -128 12 49 52 -16 -37 -0.44 24 -20
Net Cash From Operating Activities
-12 -81 -18 -16 -38 3.46 -30 23 -23 -3.92
Net Cash From Continuing Operating Activities
-12 -81 -18 -16 -38 3.46 -30 23 -23 -3.92
Net Income / (Loss) Continuing Operations
-33 -56 -53 -43 -22 -34 -48 -16 -6.73 15
Consolidated Net Income / (Loss)
-33 -56 -53 -43 -22 -34 -48 -16 -6.73 15
Depreciation Expense
1.29 1.31 1.26 2.21 2.23 2.18 2.15 2.18 2.17 2.04
Amortization Expense
0.67 0.67 0.67 0.69 0.72 0.54 0.53 0.56 0.57 0.60
Non-Cash Adjustments To Reconcile Net Income
22 23 41 29 11 20 38 25 25 22
Changes in Operating Assets and Liabilities, net
-2.55 -50 -7.84 -4.52 -31 14 -22 11 -44 -44
Net Cash From Investing Activities
75 -67 36 50 36 -24 7.54 -22 34 -20
Net Cash From Continuing Investing Activities
75 -67 36 50 36 -24 7.54 -22 34 -20
Purchase of Property, Plant & Equipment
0.14 -2.68 -1.94 -2.20 -1.57 -1.73 -1.81 -1.10 -0.36 -0.29
Purchase of Investments
-1.48 -143 -17 -20 -17 -39 -30 -44 -4.91 -36
Sale and/or Maturity of Investments
76 76 55 72 54 16 39 23 40 16
Net Cash From Financing Activities
-0.56 0.56 -7.83 24 38 8.21 -13 -0.86 18 1.10
Net Cash From Continuing Financing Activities
-0.56 0.56 -7.83 24 38 8.21 -13 -0.86 18 1.10
Issuance of Common Equity
- - 2.35 24 37 - 0.00 - 19 0.41
Other Financing Activities, net
-0.56 0.56 -10 -0.53 1.06 29 -13 -0.86 -0.96 0.68
Cash Interest Paid
8.95 10 11 12 12 0.64 12 12 24 11
Cash Income Taxes Paid
0.23 0.67 0.18 5.80 0.50 2.05 0.64 0.49 1.60 5.49

Annual Balance Sheets for Amicus Therapeutics

This table presents Amicus Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets
908 1,037 627 790 850 887 905 724 778 785
Total Current Assets
217 340 392 551 520 579 597 424 483 505
Cash & Equivalents
69 187 49 80 143 163 245 149 247 214
Short-Term Investments
145 143 310 424 310 320 237 145 39 36
Accounts Receivable
- 1.30 9.46 22 33 47 53 66 88 101
Inventories, net
0.00 3.42 4.62 8.39 14 20 27 24 60 119
Prepaid Expenses
2.57 4.99 19 17 20 30 35 40 50 35
Plant, Property, & Equipment, net
6.18 9.82 9.06 11 48 44 42 31 32 29
Total Noncurrent Assets
686 687 226 227 282 263 266 270 263 251
Goodwill
198 198 198 198 198 198 198 198 198 198
Intangible Assets
487 487 23 23 23 23 23 23 20 17
Other Noncurrent Operating Assets
1.11 2.47 5.20 6.68 62 42 45 49 45 36
Total Liabilities & Shareholders' Equity
908 1,037 627 790 850 887 905 724 778 785
Total Liabilities
561 677 274 447 374 600 598 601 618 591
Total Current Liabilities
74 111 70 86 129 130 146 139 168 149
Accounts Payable
32 41 54 81 22 17 22 15 15 13
Accrued Expenses
- - - - 100 97 98 94 144 127
Other Current Liabilities
- - - - 7.19 6.87 7.41 8.55 8.32 8.46
Total Noncurrent Liabilities
487 566 204 361 245 470 452 462 450 442
Long-Term Debt
- 154 164 322 150 389 389 392 388 390
Other Noncurrent Operating Liabilities
233 216 19 23 82 69 52 70 62 52
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
348 360 353 343 476 286 307 123 160 194
Total Preferred & Common Equity
348 360 353 343 476 286 307 123 160 194
Total Common Equity
348 360 353 343 476 286 307 123 160 194
Common Stock
919 1,122 1,402 1,742 2,230 2,311 2,598 2,668 2,839 2,929
Retained Earnings
-580 -780 -1,064 -1,412 -1,769 -2,045 -2,296 -2,532 -2,684 -2,740
Accumulated Other Comprehensive Income / (Loss)
-0.12 2.05 -2.10 0.07 2.83 8.23 4.98 -12 5.24 5.10
Other Equity Adjustments
8.76 16 16 13 12 12 0.08 0.08 0.07 0.07

Quarterly Balance Sheets for Amicus Therapeutics

This table presents Amicus Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
760 701 730 764 722 749 787
Total Current Assets
459 400 433 463 431 462 498
Cash & Equivalents
278 161 211 263 210 209 234
Short-Term Investments
77 107 54 17 30 51 16
Accounts Receivable
52 68 64 73 76 85 98
Inventories, net
13 27 51 57 61 81 115
Prepaid Expenses
38 37 52 53 54 35 35
Plant, Property, & Equipment, net
32 31 30 31 32 31 30
Total Noncurrent Assets
269 269 267 270 258 257 258
Goodwill
198 198 198 198 198 198 198
Intangible Assets
23 23 22 21 20 19 18
Other Noncurrent Operating Assets
48 49 47 51 41 40 42
Total Liabilities & Shareholders' Equity
760 701 730 764 722 749 787
Total Liabilities
627 598 619 631 591 617 608
Total Current Liabilities
165 138 159 169 142 168 158
Accounts Payable
12 25 14 23 9.21 32 13
Accrued Expenses
125 93 125 139 125 128 136
Other Current Liabilities
7.54 8.01 7.84 7.77 8.27 8.11 8.54
Total Noncurrent Liabilities
462 460 459 461 449 449 450
Long-Term Debt
391 393 393 394 388 389 389
Other Noncurrent Operating Liabilities
60 61 60 61 61 60 60
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
133 103 112 133 131 133 179
Total Preferred & Common Equity
133 103 112 133 131 133 179
Total Common Equity
133 103 112 133 131 133 179
Common Stock
2,648 2,695 2,736 2,790 2,856 2,872 2,909
Retained Earnings
-2,477 -2,585 -2,629 -2,650 -2,732 -2,748 -2,755
Accumulated Other Comprehensive Income / (Loss)
-39 -6.74 4.16 -6.77 6.64 8.79 25
Other Equity Adjustments
0.08 0.08 0.07 0.07 0.07 0.07 0.07

Annual Metrics and Ratios for Amicus Therapeutics

This table displays calculated financial ratios and metrics derived from Amicus Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
-100.00% 0.00% 644.86% 0.00% 0.00% 43.16% 17.11% 7.76% 21.30% 32.29%
EBITDA Growth
-92.82% -49.69% -117.82% 23.83% -5.59% 28.11% 17.91% 0.33% 58.69% 131.77%
EBIT Growth
-91.15% -52.12% -118.00% 22.67% -3.01% 26.56% 17.93% 0.66% 55.23% 116.58%
NOPAT Growth
-89.86% -39.45% -143.00% 17.66% 7.52% 18.76% 16.42% -2.75% 63.60% 132.22%
Net Income Growth
-91.68% -51.41% -41.97% -22.88% -2.12% 22.32% 9.53% 5.55% 35.92% 62.99%
EPS Growth
-29.03% -24.17% -24.16% 0.00% 0.00% 27.70% 14.02% 10.87% 37.80% 64.71%
Operating Cash Flow Growth
-93.81% -49.94% -42.32% -40.37% 16.52% 6.84% 13.20% 17.74% 58.52% 50.95%
Free Cash Flow Firm Growth
-814.54% 55.72% -56.33% -8.64% -0.77% 10.88% 12.24% 10.29% 53.85% 24.73%
Invested Capital Growth
764.81% 10.87% -30.58% -3.81% 7.91% 16.21% 15.83% 4.17% 7.81% 27.64%
Revenue Q/Q Growth
-100.00% 133.10% 47.53% 0.00% 0.00% 6.22% 3.94% 1.84% 7.25% 7.01%
EBITDA Q/Q Growth
-18.47% -10.91% -3.55% -1.30% -7.56% 8.05% -0.23% 5.30% 40.13% 1,617.54%
EBIT Q/Q Growth
-18.39% -12.43% -3.87% -1.44% -6.55% 7.26% 0.29% 5.18% 36.98% 264.89%
NOPAT Q/Q Growth
-17.46% -2.26% -5.31% -0.55% -6.87% 8.92% -3.67% 12.32% 33.35% 377.19%
Net Income Q/Q Growth
-20.12% -8.55% -3.86% -2.61% -3.38% 6.21% -4.98% 10.38% 12.69% 46.41%
EPS Q/Q Growth
-11.11% -3.47% -1.09% 0.00% 6.92% 4.46% -2.22% 10.87% 13.56% 47.06%
Operating Cash Flow Q/Q Growth
-26.54% 2.54% -24.05% 3.96% 1.12% 3.32% -11.38% -6.56% 54.94% -27.81%
Free Cash Flow Firm Q/Q Growth
-18.53% 19.98% -17.64% 10.55% -8.26% 2.57% -6.89% -18.97% 47.50% 19.06%
Invested Capital Q/Q Growth
19.04% -2.36% 9.14% -7.85% -5.53% 0.75% 3.44% 28.49% 6.00% 4.91%
Profitability Metrics
- - - - - - - - - -
Gross Margin
0.00% 83.20% 83.11% 0.00% 87.95% 88.10% 88.72% 88.28% 90.65% 89.98%
EBITDA Margin
0.00% -3,913.96% -1,144.55% 0.00% -186.55% -93.69% -65.67% -60.74% -20.69% 4.97%
Operating Margin
0.00% -3,668.62% -1,196.82% 0.00% -166.84% -94.68% -67.57% -64.43% -19.33% 4.71%
EBIT Margin
0.00% -4,033.58% -1,180.55% 0.00% -190.57% -97.76% -68.52% -63.16% -23.31% 2.92%
Profit (Net Income) Margin
0.00% -4,034.73% -769.03% 0.00% -195.56% -106.12% -81.98% -71.85% -37.96% -10.62%
Tax Burden Percent
100.00% 98.17% 63.24% 99.97% 100.13% 100.95% 103.69% 97.74% 100.99% 195.11%
Interest Burden Percent
100.49% 101.90% 103.01% 103.54% 102.48% 107.53% 115.39% 116.40% 161.23% -186.30%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% -55.70% -151.95% 0.00% -127.56% -92.35% -66.53% -62.39% -21.42% 5.84%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 2.28% -168.56% 0.00% -68.44% -38.81% 66.45% -448.95% -109.50% -54.96%
Return on Net Nonoperating Assets (RNNOA)
0.00% -0.81% 72.29% 0.00% 40.56% 19.76% -17.83% -47.54% -85.62% -37.52%
Return on Equity (ROE)
-56.22% -56.51% -79.66% -100.32% -86.99% -72.59% -84.37% -109.93% -107.04% -31.68%
Cash Return on Invested Capital (CROIC)
-157.16% -66.01% -115.85% -136.72% -135.16% -107.34% -81.20% -66.48% -28.94% -18.44%
Operating Return on Assets (OROA)
0.00% -20.56% -52.41% 0.00% -42.35% -29.37% -23.37% -25.53% -12.40% 1.98%
Return on Assets (ROA)
0.00% -20.57% -34.14% 0.00% -43.46% -31.88% -27.96% -29.04% -20.18% -7.18%
Return on Common Equity (ROCE)
-56.22% -56.51% -79.66% -100.32% -86.99% -72.59% -84.37% -109.93% -107.04% -31.68%
Return on Equity Simple (ROE_SIMPLE)
-37.98% -55.54% -80.49% -101.77% -74.80% -96.67% -81.49% -192.26% -94.64% -28.91%
Net Operating Profit after Tax (NOPAT)
-91 -127 -309 -230 -213 -173 -145 -148 -54 17
NOPAT Margin
0.00% -2,568.03% -837.77% 0.00% -116.79% -66.27% -47.30% -45.10% -13.53% 3.30%
Net Nonoperating Expense Percent (NNEP)
-28.56% -57.99% 16.61% -64.52% -59.12% -53.54% -132.98% 386.56% 88.08% 60.80%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - -27.68% -9.86% 2.98%
Cost of Revenue to Revenue
0.00% 16.80% 16.89% 0.00% 12.05% 11.90% 11.28% 11.72% 9.35% 10.02%
SG&A Expenses to Revenue
0.00% 1,435.07% 240.11% 0.00% 93.21% 59.95% 63.08% 64.71% 68.93% 61.21%
R&D to Revenue
0.00% 2,113.61% 404.31% 0.00% 157.15% 118.23% 89.05% 84.04% 38.16% 20.70%
Operating Expenses to Revenue
0.00% 3,751.82% 1,279.93% 0.00% 254.78% 182.78% 156.37% 152.70% 109.99% 85.27%
Earnings before Interest and Taxes (EBIT)
-131 -200 -436 -337 -347 -255 -209 -208 -93 15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-130 -194 -423 -322 -340 -244 -201 -200 -83 26
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
3.48 1.96 6.78 0.00 5.21 21.01 10.47 27.88 25.98 14.51
Price to Tangible Book Value (P/TBV)
0.00 0.00 18.12 0.00 9.71 91.75 37.17 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 142.67 64.79 0.00 13.62 23.06 10.53 10.42 10.42 5.33
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
4.79 2.44 13.22 0.00 12.58 29.47 13.49 14.62 16.28 8.84
Enterprise Value to Revenue (EV/Rev)
0.00 118.51 59.75 0.00 11.95 22.74 10.29 10.78 10.67 5.59
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 112.59
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 191.44
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 169.69
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.12 0.58 0.49 0.94 0.31 1.39 1.33 3.36 2.42 2.01
Long-Term Debt to Equity
0.00 0.43 0.47 0.94 0.31 1.36 1.27 3.19 2.42 2.01
Financial Leverage
-0.61 -0.35 -0.43 -0.53 -0.59 -0.51 -0.27 0.11 0.78 0.68
Leverage Ratio
2.38 2.75 2.33 2.04 2.00 2.28 3.02 3.79 5.30 4.41
Compound Leverage Factor
2.39 2.80 2.40 2.11 2.05 2.45 3.48 4.41 8.55 -8.22
Debt to Total Capital
10.64% 36.89% 32.84% 48.41% 23.89% 58.16% 57.05% 77.06% 70.77% 66.78%
Short-Term Debt to Total Capital
10.64% 9.83% 1.60% 0.00% 0.00% 1.30% 2.64% 3.99% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 27.06% 31.25% 48.41% 23.89% 56.86% 54.41% 73.07% 70.77% 66.78%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
89.36% 63.11% 67.16% 51.59% 76.11% 41.84% 42.95% 22.94% 29.23% 33.22%
Debt to EBITDA
-0.32 -1.09 -0.41 -1.00 -0.44 -1.63 -2.03 -2.07 -4.70 14.86
Net Debt to EBITDA
1.33 0.62 0.44 0.57 0.89 0.35 0.37 -0.60 -1.23 5.34
Long-Term Debt to EBITDA
0.00 -0.80 -0.39 -1.00 -0.44 -1.59 -1.94 -1.96 -4.70 14.86
Debt to NOPAT
-0.45 -1.65 -0.56 -1.40 -0.70 -2.30 -2.83 -2.78 -7.18 22.40
Net Debt to NOPAT
1.89 0.94 0.60 0.79 1.42 0.49 0.51 -0.81 -1.88 8.05
Long-Term Debt to NOPAT
0.00 -1.21 -0.53 -1.40 -0.70 -2.25 -2.69 -2.64 -7.18 22.40
Altman Z-Score
0.11 -0.79 1.24 -3.20 0.49 2.74 -0.15 -1.49 -0.18 -0.75
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
2.94 3.06 5.60 6.40 4.04 4.47 4.09 3.05 2.88 3.39
Quick Ratio
2.91 2.99 5.25 6.11 3.77 4.09 3.67 2.59 2.23 2.36
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-341 -151 -236 -224 -226 -201 -176 -158 -73 -55
Operating Cash Flow to CapEx
-2,078.87% -2,523.05% -4,721.50% -4,755.15% -1,251.33% -7,229.32% -5,213.47% -46,922.54% -928.64% -953.87%
Free Cash Flow to Firm to Interest Expense
-215.92 -27.95 -13.68 -9.99 -11.95 -8.96 -5.43 -4.26 -1.14 -1.11
Operating Cash Flow to Interest Expense
-63.46 -27.82 -12.40 -13.39 -13.27 -10.40 -6.24 -4.49 -1.08 -0.68
Operating Cash Flow Less CapEx to Interest Expense
-66.51 -28.92 -12.66 -13.67 -14.33 -10.55 -6.36 -4.50 -1.19 -0.75
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.00 0.01 0.04 0.00 0.22 0.30 0.34 0.40 0.53 0.68
Accounts Receivable Turnover
0.00 0.00 6.86 0.00 6.60 6.51 6.14 5.54 5.19 5.60
Inventory Turnover
0.00 0.00 1.55 0.00 1.96 1.85 1.49 1.52 0.89 0.59
Fixed Asset Turnover
0.00 0.62 3.91 0.00 6.17 5.70 7.08 8.99 12.79 17.31
Accounts Payable Turnover
0.00 0.02 0.13 0.00 0.43 1.60 1.79 2.09 2.45 3.77
Days Sales Outstanding (DSO)
0.00 0.00 53.21 0.00 55.33 56.11 59.49 65.89 70.30 65.20
Days Inventory Outstanding (DIO)
0.00 0.00 235.27 0.00 186.39 197.51 245.55 239.40 408.32 615.23
Days Payable Outstanding (DPO)
0.00 16,042.47 2,777.24 0.00 850.45 228.01 204.26 174.59 149.29 96.75
Cash Conversion Cycle (CCC)
0.00 -16,042.47 -2,488.76 0.00 -608.73 25.61 100.78 130.70 329.33 583.68
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
217 240 167 161 173 201 233 243 262 334
Invested Capital Turnover
0.00 0.02 0.18 0.00 1.09 1.39 1.41 1.38 1.58 1.77
Increase / (Decrease) in Invested Capital
249 24 -74 -6.36 13 28 32 9.73 19 72
Enterprise Value (EV)
1,039 588 2,207 -182 2,179 5,932 3,144 3,550 4,263 2,955
Market Capitalization
1,212 707 2,393 0.00 2,482 6,017 3,218 3,430 4,161 2,815
Book Value per Share
$2.78 $2.53 $2.12 $0.00 $1.87 $1.10 $1.10 $0.44 $0.55 $0.65
Tangible Book Value per Share
($2.70) ($2.28) $0.79 $0.00 $1.00 $0.25 $0.31 ($0.35) ($0.20) ($0.07)
Total Capital
389 571 525 665 626 685 716 536 548 584
Total Debt
41 211 173 322 150 398 408 413 388 390
Total Long-Term Debt
0.00 154 164 322 150 389 389 392 388 390
Net Debt
-173 -120 -186 -182 -303 -85 -74 120 102 140
Capital Expenditures (CapEx)
4.82 5.95 4.53 6.31 20 3.23 3.88 0.36 7.44 3.55
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-30 -45 -28 -39 -61 -25 -13 13 29 106
Debt-free Net Working Capital (DFNWC)
184 285 330 465 391 459 470 306 315 356
Net Working Capital (NWC)
143 229 322 465 391 450 451 285 315 356
Net Nonoperating Expense (NNE)
41 73 -25 119 144 104 106 88 98 74
Net Nonoperating Obligations (NNO)
-131 -120 -186 -182 -303 -85 -74 120 102 140
Total Depreciation and Amortization (D&A)
1.83 5.93 13 15 7.32 11 8.70 7.98 10 11
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -910.55% -76.46% 0.00% -33.74% -9.42% -4.17% 3.83% 7.30% 20.08%
Debt-free Net Working Capital to Revenue
0.00% 5,752.44% 894.46% 0.00% 214.70% 175.82% 153.76% 93.01% 78.97% 67.39%
Net Working Capital to Revenue
0.00% 4,620.92% 871.72% 0.00% 214.70% 172.41% 147.57% 86.50% 78.97% 67.39%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($1.20) ($1.49) ($1.85) $0.00 ($1.48) ($1.07) ($0.92) ($0.82) ($0.51) ($0.18)
Adjusted Weighted Average Basic Shares Outstanding
125.21M 194.82M 186.89M 0.00 257.24M 264.32M 271.42M 289.06M 295.16M 304.38M
Adjusted Diluted Earnings per Share
($1.20) ($1.49) ($1.85) $0.00 ($1.48) ($1.07) ($0.92) ($0.82) ($0.51) ($0.18)
Adjusted Weighted Average Diluted Shares Outstanding
125.21M 194.82M 186.89M 0.00 257.24M 264.32M 271.42M 289.06M 295.16M 304.38M
Adjusted Basic & Diluted Earnings per Share
($1.20) ($1.49) ($1.85) ($1.88) ($1.48) ($1.07) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
109.92M 134.40M 153.36M 185.79M 240.42M 258.87M 280.03M 282.71M 295.38M 300.12M
Normalized Net Operating Profit after Tax (NOPAT)
-88 -123 -148 -228 -211 -171 -140 -143 -51 24
Normalized NOPAT Margin
0.00% -2,471.62% -399.72% 0.00% -115.52% -65.43% -45.81% -43.46% -12.88% 4.51%
Pre Tax Income Margin
0.00% -4,110.15% -1,216.14% 0.00% -195.30% -105.12% -79.06% -73.52% -37.59% -5.44%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-83.31 -37.05 -25.29 -15.05 -18.40 -11.37 -6.45 -5.60 -1.45 0.31
NOPAT to Interest Expense
-57.86 -23.59 -17.95 -10.27 -11.28 -7.71 -4.45 -4.00 -0.84 0.35
EBIT Less CapEx to Interest Expense
-86.37 -38.15 -25.55 -15.33 -19.46 -11.52 -6.57 -5.61 -1.57 0.24
NOPAT Less CapEx to Interest Expense
-60.91 -24.69 -18.21 -10.55 -12.34 -7.85 -4.57 -4.01 -0.96 0.28
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Amicus Therapeutics

This table displays calculated financial ratios and metrics derived from Amicus Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
2.70% 7.23% 9.60% 17.06% 26.70% 30.63% 27.97% 34.04% 36.73% 30.09%
EBITDA Growth
54.36% 15.95% 41.31% 47.69% 43.89% 93.89% 28.40% 152.08% 306.43% 686.17%
EBIT Growth
52.08% 15.71% 40.32% 44.21% 34.72% 89.63% 25.41% 137.80% 239.47% 392.34%
NOPAT Growth
20.19% 41.33% 50.04% 68.88% 49.70% 91.28% 26.34% -16,377.37% -80.26% 1,248.02%
Net Income Growth
33.82% 32.92% 37.92% 30.45% 35.18% 39.42% 8.53% 63.69% 68.81% 143.55%
EPS Growth
36.84% 34.48% 40.00% 28.57% 41.67% 42.11% 11.11% 66.67% 71.43% 145.45%
Operating Cash Flow Growth
50.95% -14.55% 69.01% -1.71% -229.84% 104.28% -64.34% 240.65% 40.10% -213.24%
Free Cash Flow Firm Growth
122.94% 52.22% 34.19% -3,317.40% -651.19% 45.23% -90.06% -3,065.39% -33.08% -98.12%
Invested Capital Growth
-16.14% 4.17% 1.79% 28.40% 30.68% 7.81% 16.07% 3.60% 28.97% 27.64%
Revenue Q/Q Growth
1.19% 7.84% -2.07% 9.54% 9.52% 11.19% -4.07% 14.73% 11.72% 5.79%
EBITDA Q/Q Growth
64.46% -223.11% 28.95% 35.89% 61.88% 64.83% -732.93% 146.64% 51.09% -0.12%
EBIT Q/Q Growth
62.12% -201.67% 28.10% 32.09% 55.68% 52.08% -417.20% 134.42% 63.52% 0.43%
NOPAT Q/Q Growth
44.17% -25.08% 11.08% 49.89% 9.74% 78.31% -650.84% -11,110.39% 99.01% 238.12%
Net Income Q/Q Growth
46.45% -67.83% 5.25% 18.33% 50.09% -56.85% -43.07% 67.58% 57.13% 319.04%
EPS Q/Q Growth
42.86% -58.33% 5.26% 16.67% 53.33% -57.14% -45.45% 68.75% 60.00% 350.00%
Operating Cash Flow Q/Q Growth
26.71% -594.75% 77.63% 10.71% -137.69% 109.02% -958.73% 176.41% -201.23% 82.95%
Free Cash Flow Firm Q/Q Growth
491.31% -410.33% 22.33% -125.76% -1.30% 69.16% -169.50% -3,659.99% 95.74% 54.09%
Invested Capital Q/Q Growth
-3.81% 28.49% -0.85% 4.78% -2.10% 6.00% 6.74% -6.47% 21.87% 4.91%
Profitability Metrics
- - - - - - - - - -
Gross Margin
83.55% 89.35% 91.95% 90.36% 90.39% 90.16% 87.71% 91.11% 90.62% 90.09%
EBITDA Margin
-22.34% -66.94% -48.57% -28.43% -9.89% -3.13% -27.18% 11.05% 14.94% 14.10%
Operating Margin
-41.42% -48.05% -43.63% -19.96% -16.45% -3.21% -25.11% 11.82% 15.30% 10.67%
EBIT Margin
-24.73% -69.19% -50.80% -31.49% -12.74% -5.49% -29.61% 8.88% 13.00% 12.34%
Profit (Net Income) Margin
-40.75% -63.41% -61.36% -45.75% -20.85% -29.41% -43.86% -12.39% -4.75% 9.85%
Tax Burden Percent
113.75% 79.72% 99.46% 106.70% 87.34% 106.90% 111.10% -14,534.26% -99.17% 185.77%
Interest Burden Percent
144.82% 114.97% 121.44% 136.14% 187.30% 500.95% 133.33% 0.96% 36.88% 42.94%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 14,634.26% 199.17% -85.77%
Return on Invested Capital (ROIC)
-45.24% -46.53% -43.09% -21.82% -19.66% -3.55% -28.61% -3,046.53% -26.50% 35.13%
ROIC Less NNEP Spread (ROIC-NNEP)
-24.99% -161.66% -82.14% -58.49% -31.02% -31.78% -48.83% -1,444.45% -14.86% 22.78%
Return on Net Nonoperating Assets (RNNOA)
4.65% -17.12% -32.78% -33.62% -19.86% -24.85% -60.08% -1,595.36% -12.07% 15.55%
Return on Equity (ROE)
-40.59% -63.64% -75.87% -55.44% -39.53% -28.41% -88.69% -4,641.89% -38.57% 50.69%
Cash Return on Invested Capital (CROIC)
-64.18% -66.48% -52.92% -66.25% -63.80% -28.94% -32.98% -12.66% -24.01% -18.44%
Operating Return on Assets (OROA)
-9.32% -27.96% -22.40% -14.43% -6.23% -2.92% -17.63% 5.47% 8.28% 8.34%
Return on Assets (ROA)
-15.35% -25.63% -27.06% -20.95% -10.19% -15.64% -26.12% -7.63% -3.03% 6.66%
Return on Common Equity (ROCE)
-40.59% -63.64% -75.87% -55.44% -39.53% -28.41% -88.69% -4,641.89% -38.57% 50.69%
Return on Equity Simple (ROE_SIMPLE)
-199.13% 0.00% -199.12% -166.08% -130.30% 0.00% -112.53% -90.20% -58.54% 0.00%
Net Operating Profit after Tax (NOPAT)
-24 -30 -26 -13 -12 -2.58 -19 -2,175 -21 30
NOPAT Margin
-29.00% -33.63% -30.54% -13.97% -11.51% -2.25% -17.58% -1,717.34% -15.18% 19.82%
Net Nonoperating Expense Percent (NNEP)
-20.25% 115.14% 39.05% 36.67% 11.35% 28.23% 20.22% -1,602.08% -11.64% 12.35%
Return On Investment Capital (ROIC_SIMPLE)
- -5.52% - - - -0.47% - - - 5.08%
Cost of Revenue to Revenue
16.45% 10.65% 8.05% 9.64% 9.61% 9.84% 12.29% 8.89% 9.38% 9.91%
SG&A Expenses to Revenue
57.87% 61.61% 85.73% 69.23% 63.43% 61.03% 79.73% 58.09% 53.07% 57.89%
R&D to Revenue
64.84% 72.50% 48.10% 37.19% 39.33% 30.44% 25.66% 19.49% 18.49% 20.17%
Operating Expenses to Revenue
124.98% 137.40% 135.29% 110.31% 106.84% 93.59% 112.82% 79.29% 75.31% 79.42%
Earnings before Interest and Taxes (EBIT)
-20 -61 -44 -30 -13 -6.32 -33 11 18 18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-18 -59 -42 -27 -10 -3.60 -30 14 21 21
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
22.09 27.88 30.57 32.03 26.20 25.98 26.43 22.17 17.71 14.51
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
9.06 10.42 9.31 10.20 9.38 10.42 8.16 6.45 6.42 5.33
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
15.79 14.62 13.59 14.72 14.60 16.28 12.89 11.73 10.38 8.84
Enterprise Value to Revenue (EV/Rev)
9.23 10.78 9.72 10.60 9.68 10.67 8.51 6.73 6.70 5.59
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2,164.48 112.59
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 191.44
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 906.34 169.69
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
3.10 3.36 3.95 3.64 2.96 2.42 2.97 2.93 2.18 2.01
Long-Term Debt to Equity
2.95 3.19 3.83 3.53 2.96 2.42 2.97 2.93 2.18 2.01
Financial Leverage
-0.19 0.11 0.40 0.57 0.64 0.78 1.23 1.10 0.81 0.68
Leverage Ratio
3.37 3.79 4.48 5.37 5.73 5.30 6.10 6.06 4.97 4.41
Compound Leverage Factor
4.88 4.35 5.44 7.31 10.74 26.57 8.13 0.06 1.83 1.89
Debt to Total Capital
75.62% 77.06% 79.80% 78.46% 74.73% 70.77% 74.82% 74.59% 68.53% 66.78%
Short-Term Debt to Total Capital
3.65% 3.99% 2.49% 2.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
71.97% 73.07% 77.31% 75.95% 74.73% 70.77% 74.82% 74.59% 68.53% 66.78%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
24.38% 22.94% 20.20% 21.54% 25.27% 29.23% 25.18% 25.41% 31.47% 33.22%
Debt to EBITDA
-1.95 -2.07 -2.38 -2.78 -2.86 -4.70 -5.49 -13.03 254.90 14.86
Net Debt to EBITDA
-0.27 -0.60 -0.81 -0.96 -0.82 -1.23 -2.10 -4.32 91.45 5.34
Long-Term Debt to EBITDA
-1.85 -1.96 -2.30 -2.69 -2.86 -4.70 -5.49 -13.03 254.90 14.86
Debt to NOPAT
-2.43 -2.78 -3.32 -4.38 -4.86 -7.18 -8.24 -16.60 106.74 22.40
Net Debt to NOPAT
-0.33 -0.81 -1.13 -1.52 -1.40 -1.88 -3.16 -5.50 38.29 8.05
Long-Term Debt to NOPAT
-2.31 -2.64 -3.22 -4.24 -4.86 -7.18 -8.24 -16.60 106.74 22.40
Altman Z-Score
-0.96 -0.82 -1.30 -0.78 -0.64 0.18 -0.88 -1.15 -0.55 -0.73
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
2.78 3.05 2.89 2.72 2.73 2.88 3.03 2.75 3.15 3.39
Quick Ratio
2.47 2.59 2.42 2.07 2.09 2.23 2.22 2.05 2.20 2.36
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
13 -39 -31 -69 -70 -22 -58 -2,184 -93 -43
Operating Cash Flow to CapEx
0.00% -3,017.26% -930.43% -732.65% -2,450.29% 199.77% -1,639.70% 2,066.58% -6,452.53% -1,359.72%
Free Cash Flow to Firm to Interest Expense
1.32 -3.55 -2.58 -5.52 -5.38 -0.81 -4.67 -174.59 -7.33 -3.57
Operating Cash Flow to Interest Expense
-1.21 -7.28 -1.53 -1.29 -2.95 0.13 -2.39 1.81 -1.81 -0.33
Operating Cash Flow Less CapEx to Interest Expense
-1.19 -7.52 -1.69 -1.47 -3.07 0.06 -2.53 1.73 -1.84 -0.35
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.38 0.40 0.44 0.46 0.49 0.53 0.60 0.62 0.64 0.68
Accounts Receivable Turnover
6.23 5.54 5.59 6.03 5.93 5.19 5.86 6.12 5.76 5.60
Inventory Turnover
2.10 1.52 1.48 1.08 1.01 0.89 1.00 0.69 0.57 0.59
Fixed Asset Turnover
8.69 8.99 10.21 10.97 11.72 12.79 13.27 14.84 16.05 17.31
Accounts Payable Turnover
2.03 2.09 1.59 2.12 2.01 2.45 2.57 2.02 2.70 3.77
Days Sales Outstanding (DSO)
58.56 65.89 65.35 60.53 61.57 70.30 62.32 59.63 63.36 65.20
Days Inventory Outstanding (DIO)
174.02 239.40 246.78 339.22 362.09 408.32 364.42 525.36 636.04 615.23
Days Payable Outstanding (DPO)
179.81 174.59 230.19 171.98 181.54 149.29 141.91 180.45 135.26 96.75
Cash Conversion Cycle (CCC)
52.77 130.70 81.93 227.77 242.12 329.33 284.84 404.55 564.15 583.68
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
189 243 241 252 247 262 279 261 319 334
Invested Capital Turnover
1.56 1.38 1.41 1.56 1.71 1.58 1.63 1.77 1.75 1.77
Increase / (Decrease) in Invested Capital
-36 9.73 4.22 56 58 19 39 9.09 72 72
Enterprise Value (EV)
2,985 3,550 3,274 3,715 3,605 4,263 3,603 3,067 3,307 2,955
Market Capitalization
2,928 3,430 3,135 3,574 3,491 4,161 3,454 2,938 3,168 2,815
Book Value per Share
$0.47 $0.44 $0.36 $0.39 $0.46 $0.55 $0.43 $0.45 $0.60 $0.65
Tangible Book Value per Share
($0.31) ($0.35) ($0.42) ($0.38) ($0.30) ($0.20) ($0.29) ($0.28) ($0.12) ($0.07)
Total Capital
544 536 508 518 527 548 519 521 568 584
Total Debt
411 413 405 406 394 388 388 389 389 390
Total Long-Term Debt
391 392 393 393 394 388 388 389 389 390
Net Debt
56 120 138 141 114 102 149 129 140 140
Capital Expenditures (CapEx)
-0.14 2.68 1.94 2.20 1.57 1.73 1.81 1.10 0.36 0.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-41 13 6.87 21 14 29 50 34 91 106
Debt-free Net Working Capital (DFNWC)
314 306 274 287 294 315 289 294 340 356
Net Working Capital (NWC)
294 285 261 274 294 315 289 294 340 356
Net Nonoperating Expense (NNE)
9.60 26 27 30 9.66 31 29 -2,160 -15 15
Net Nonoperating Obligations (NNO)
56 120 138 141 114 102 149 129 140 140
Total Depreciation and Amortization (D&A)
1.95 1.98 1.92 2.90 2.95 2.72 2.69 2.74 2.74 2.64
Debt-free, Cash-free Net Working Capital to Revenue
-12.68% 3.83% 2.04% 5.98% 3.63% 7.30% 11.70% 7.37% 18.35% 20.08%
Debt-free Net Working Capital to Revenue
97.04% 93.01% 81.35% 81.75% 78.90% 78.97% 68.28% 64.44% 68.94% 67.39%
Net Working Capital to Revenue
90.91% 86.50% 77.59% 78.04% 78.90% 78.97% 68.28% 64.44% 68.94% 67.39%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.12) ($0.19) ($0.18) ($0.15) ($0.07) ($0.11) ($0.16) ($0.05) ($0.02) $0.05
Adjusted Weighted Average Basic Shares Outstanding
289.22M 289.06M 291.34M 292.80M 295.76M 295.16M 302.90M 303.77M 304.69M 304.38M
Adjusted Diluted Earnings per Share
($0.12) ($0.19) ($0.18) ($0.15) ($0.07) ($0.11) ($0.16) ($0.05) ($0.02) $0.05
Adjusted Weighted Average Diluted Shares Outstanding
289.22M 289.06M 291.34M 292.80M 295.76M 295.16M 302.90M 303.77M 304.69M 304.38M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
280.95M 282.71M 284.58M 287.12M 293.25M 295.38M 296.20M 296.59M 298.81M 300.12M
Normalized Net Operating Profit after Tax (NOPAT)
-23 -29 -26 -12 -11 -2.58 -15 10 17 11
Normalized NOPAT Margin
-28.51% -32.37% -30.54% -12.88% -10.16% -2.25% -13.74% 8.27% 12.27% 7.47%
Pre Tax Income Margin
-35.82% -79.55% -61.69% -42.87% -23.87% -27.51% -39.48% 0.09% 4.79% 5.30%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-2.10 -5.49 -3.70 -2.38 -1.02 -0.24 -2.63 0.90 1.45 1.55
NOPAT to Interest Expense
-2.46 -2.67 -2.22 -1.06 -0.92 -0.10 -1.56 -173.86 -1.69 2.48
EBIT Less CapEx to Interest Expense
-2.09 -5.74 -3.86 -2.56 -1.14 -0.30 -2.77 0.81 1.42 1.52
NOPAT Less CapEx to Interest Expense
-2.45 -2.91 -2.39 -1.23 -1.04 -0.16 -1.71 -173.95 -1.72 2.46
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Amicus Therapeutics' Financials

When does Amicus Therapeutics's financial year end?

According to the most recent income statement we have on file, Amicus Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Amicus Therapeutics' net income changed over the last 8 years?

Amicus Therapeutics' net income appears to be on a downward trend, with a most recent value of -$56.11 million in 2024, falling from -$132.12 million in 2015. The previous period was -$151.58 million in 2023.

What is Amicus Therapeutics's operating income?
Amicus Therapeutics's total operating income in 2024 was $24.88 million, based on the following breakdown:
  • Total Gross Profit: $475.35 million
  • Total Operating Expenses: $450.48 million
How has Amicus Therapeutics revenue changed over the last 8 years?

Over the last 8 years, Amicus Therapeutics' total revenue changed from $0.00 in 2015 to $528.30 million in 2024, a change of 52,829,500,000.0%.

How much debt does Amicus Therapeutics have?

Amicus Therapeutics' total liabilities were at $590.99 million at the end of 2024, a 4.3% decrease from 2023, and a 5.4% increase since 2015.

How much cash does Amicus Therapeutics have?

In the past 9 years, Amicus Therapeutics' cash and equivalents has ranged from $49.06 million in 2017 to $246.99 million in 2023, and is currently $213.75 million as of their latest financial filing in 2024.

How has Amicus Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Amicus Therapeutics' book value per share changed from 2.78 in 2015 to 0.65 in 2024, a change of -76.7%.

Remove Ads


This page (NASDAQ:FOLD) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners